{
    "study_accession": "SDY661",
    "actual_completion_date": null,
    "actual_enrollment": 20,
    "actual_start_date": "2003-01-01",
    "age_unit": "Years",
    "brief_description": "This study will test the safety of a new drug called RG2077 that is designed to treat MS.  The study will not determine whether RG2077 is effective in treating MS, only whether it is safe.",
    "brief_title": "Khoury ITN006AI: NMS02 Safety of RG2007 (CTLA4-IgG4m) in Patients with Multiple Sclerosis",
    "clinical_trial": "Y",
    "condition_studied": "Multiple sclerosis",
    "dcl_id": 2,
    "description": "Safety study of subjects diagnosed with relapsing-remitting multiple sclerosis treated with escalating intravenous doses of CTLA4-IgG4m (RG2077)",
    "doi": "10.21430/M3YYEBXJ0L",
    "endpoints": "Safety assessment, neurological and physical examinations",
    "gender_included": "Female, Male",
    "hypothesis": "RG2077 will arrest MS if administered early in the course of MS and decrease accumulation of lesions on MRI.",
    "initial_data_release_date": "2015-12-14",
    "initial_data_release_version": "DR16",
    "intervention_agent": "RG2077 CTLA4-IgG4m T cell costimulation pathway blocker",
    "latest_data_release_date": "2015-12-14",
    "latest_data_release_version": "DR16",
    "maximum_age": "  54.00",
    "minimum_age": "  22.00",
    "objectives": "Evaluate the safety of RG2077 treatment in subjects with MS",
    "official_title": "A Phase I Study:  Safety of RG2077 (CTLA4-IgG4m) in Patients with Relapsing-Remitting Multiple Sclerosis",
    "sponsoring_organization": "NIAID",
    "target_enrollment": 20,
    "workspace_id": 4117,
    "research_focus": [
        "Autoimmune"
    ],
    "arm": [
        {
            "arm_accession": "ARM2917",
            "description": "Single IV infusion with 2mg/kg RG2077",
            "name": "RG2077.2mg"
        },
        {
            "arm_accession": "ARM2918",
            "description": "Single IV infusion with 10mg/kg RG2077",
            "name": "RG2077.10mg"
        },
        {
            "arm_accession": "ARM2919",
            "description": "Single IV infusion with 20mg/kg RG2077",
            "name": "RG2077.20mg"
        },
        {
            "arm_accession": "ARM2920",
            "description": "Single IV infusion with 35mg/kg RG2077",
            "name": "RG2077.35mg"
        },
        {
            "arm_accession": "ARM2921",
            "description": "Four IV infusions with 10mg/kg RG2077",
            "name": "RG2077.4x10m"
        }
    ],
    "personnel": [
        {
            "first_name": "Samia",
            "last_name": "Khoury",
            "organization": "Brigham and Women's Hospital",
            "role_in_study": "Principal Investigator",
            "site_name": "Immune Tolerance Network"
        }
    ],
    "pubmed": [
        {
            "title": "CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial.",
            "journal": "Neurology.",
            "month": "Sep",
            "year": "2008",
            "doi": "10.1212/01.wnl.0000325915.00112.61.",
            "pubmed_id": "18794494"
        }
    ],
    "program": [
        {
            "program_name": "ITN: Collaborative Network for Clinical Research on Immune Tolerance Network",
            "contract_name": "Immune Tolerance Network"
        }
    ],
    "assay": [],
    "subject": {
        "race": [
            {
                "race": "Black or African American",
                "count": 2
            },
            {
                "race": "White",
                "count": 18
            }
        ],
        "gender": [
            {
                "Female": 19
            },
            {
                "Male": 1
            }
        ]
    }
}
